News

Quotient's Head of Production, Drug Substance, Paul Quigley was featured in a interview with Pharmaceutical Technology regarding the acceleration of development timelines between drug substance and drug product.

Quotient's VP of Bioanalytical Services, Stuart McDougall was featured in an interview with Clinical Trials Area discussing the Bioanalytical and Pharmacokinetics (PK) strategies at Quotient, and how we reduce risk and delay within the drug development process.

Oxilio OXL001 formulation optimisation and clinical trial preparation contract with Quotient Sciences Oxilio Ltd is a privately held pharmaceutical development company focused on repurposing known drugs for the treatment of cancer through a programme of corporate alliances coupled with rapid proof of concept clinical development.

Quotient Sciences completes integration of drug substance into Translational Pharmaceutics® Platform. The newly enhanced drug development platform will help empower innovators with the fastest[1] development timelines

Quotient Sciences drug development experts, Chris Roe & Vanessa Zann, are contributing co-authors in new biopharmaceutics textbook. Published by Wiley, "Biopharmaceutics - From Fundamentals to Industrial Practice," was written by a group of distinguished Scientists from the UK's Academy of Pharmaceutical Sciences Biopharmaceutica Focus Group and edited by Professor of Biopharmaceutics, Hannah Batchelor. The textbook is designed to deliver a comprehensive examination of the tools used within the field of biopharmaceutics and their applications to drug development.

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is leased to announce that following the Company's signing of an exclusive global licensing agreement with Oxilio Ltd ("Oxilio") for NXP001 on 13 September 2021, Oxilio has progressed the product and signed a significant service contract with Quotient Sciences Ltd ("Quotient Sciences") to support the formulation development of NXP001.